Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma

Acta Neuropathologica

Volumn 130, Issue 4, 2015, Pages 587-597

  Liu, Qun ^a,b   Liu, Yuexin ^a   Li, Wenliang ^b   Wang, Xiaoguang ^b   Sawaya, Raymond ^a   Lang, Frederick F ^a   Yung, W K Alfred ^a   Chen, Kexin ^b   Fuller, Gregory N ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome b5 reductase 2; DNA methylation; Isocitrate dehydrogenase 1; Magnetic resonance imaging; Multicentric glioma; Multifocal glioma; Mutation

Indexed keywords

ATRX PROTEIN; CYTOCHROME B5 REDUCTASE; CYTOCHROME B5 REDUCTASE 2; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDES AND PROTEINS; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ATRX PROTEIN, HUMAN; DNA HELICASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NUCLEAR PROTEIN;

ADULT; ARTICLE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORPUS CALLOSUM; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE DOSAGE; GLIOBLASTOMA; HEMISPHERE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTRIC GLIOBLASTOMA; MULTIFOCAL GLIOBLASTOMA; MULTIPLE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SOMATIC MUTATION; SURVIVAL RATE; TUMOR INVASION; BRAIN; BRAIN NEOPLASMS; COHORT ANALYSIS; FACTUAL DATABASE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BRAIN; BRAIN NEOPLASMS; COHORT STUDIES; DATABASES, FACTUAL; DNA HELICASES; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS;

EID: 84942370095     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1470-8     Document Type: Article

References (31)

1. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:829–848. doi:10.1007/s00401-015-1432-1
2. Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ, Marosi C, Dietrich P-Y, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. doi:10.1007/s00401-012-1016-2
3. Baldock AL, Yagle K, Born DE, Ahn S, Trister AD, Neal M, Johnston SK, Bridge CA, Basanta D, Scott J, Malone H, Sonabend AM, Canoll P, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR (2014) Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro Oncol 16:779–786. doi:10.1093/neuonc/nou027
4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu C-J, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Research Network TCGA (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. doi:10.1016/j.cell.2013.09.034
5. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355. doi:10.3174/ajnr.A2950
6. Cogdell D, Chung W, Liu Y, McDonald JM, Aldape K, Issa J-PJ, Fuller GN, Zhang W (2011) Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chin J Cancer 30:247–253
7. Devaney JM, Wang S, Funda S, Long J, Taghipour DJ, Tbaishat R, Furbert-Harris P, Ittmann M, Kwabi-Addo B (2013) Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. Prostate Cancer Prostatic Dis 16:292–300. doi:10.1038/pcan.2013.21
8. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307–315. doi:10.1093/bioinformatics/btg405
9. Gene Ontology Consortium (2015) Gene Ontology Consortium: going forward. Nucleic Acids Res 43:D1049–D1056. doi:10.1093/nar/gku1179
10. Giannopoulos S, Kyritsis AP (2010) Diagnosis and management of multifocal gliomas. Oncology 79:306–312. doi:10.1159/000323492
11. Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, DeMonte F, Rao G, Weinberg JS, Wildrick DM, Aldape KD, Sawaya R (2011) Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg 114:576–584. doi:10.3171/2010.6.JNS091326
12. Kong D-S, Song S-Y, Kim D-H, Joo KM, Yoo J-S, Koh JS, Dong SM, Suh Y-L, Lee J-I, Park K, Kim JH, Nam D-H (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115:140–148. doi:10.1002/cncr.23972
13. Liu X-Y, Gerges N, Korshunov A, Sabha N, Khuong-Quang D-A, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tönjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625. doi:10.1007/s00401-012-1031-3
14. Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ (2013) Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2:185–195. doi:10.1002/cam4.58
15. McKenzie JT, Guarnaschelli JN, Vagal AS, Warnick RE, Breneman JC (2013) Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neurooncol 113:403–409. doi:10.1007/s11060-013-1126-2
16. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM et al (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068. doi:10.1038/nature07385
17. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850. doi:10.1001/jama.2013.280319
18. Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK, Yu JS, Bannykh SI, Black KL, Nuño M (2012) Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 117:705–711. doi:10.3171/2012.7.JNS12147
19. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD (2014) Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol 119:429–435. doi:10.1007/s11060-014-1515-1
20. Pradere J-P, Dapito DH, Schwabe RF (2014) The Yin and Yang of Toll-like receptors in cancer. Oncogene 33:3485–3495. doi:10.1038/onc.2013.302
21. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. doi:10.1007/s00401-014-1370-3
22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. doi:10.1093/nar/gkv007
23. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio IIC, Cairns RA, McCracken S, Wakeham A, Haight J, Ten AY, Snow B, Ueda T, Inoue S, Yamamoto K, Ko M, Rao A, Yen KE, Su SM, Mak TW (2012) D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26:2038–2049. doi:10.1101/gad.198200.112
24. Shakur SF, Bit-Ivan E, Watkin WG, Merrell RT, Farhat HI (2013) Multifocal and multicentric glioblastoma with leptomeningeal gliomatosis: a case report and review of the literature. Case Rep Med 2013:1–8. doi:10.1155/2013/132679
25. Showalter TN, Andrel J, Andrews DW, Curran WJ Jr, Daskalakis C, Werner-Wasik M (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824. doi:10.1016/j.ijrobp.2007.03.045
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102:15545–15550. doi:10.1073/pnas.0506580102
27. Thomas RP, Xu LW, Lober RM, Li G, Nagpal S (2013) The incidence and significance of multiple lesions in glioblastoma. J Neurooncol 112:91–97. doi:10.1007/s11060-012-1030-1
28. Turkalp Z, Karamchandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71:1319–1325. doi:10.1001/jamaneurol.2014.1205
29. Wesseling P, van den Bent M, Perry A (2015) Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:809–827. doi:10.1007/s00401-015-1424-1
30. Wolbers JG (2014) Novel strategies in glioblastoma surgery aim at safe, supra-maximum resection in conjunction with local therapies. Chin J Cancer 33:8–15. doi:10.5732/cjc.013.10219
31. Xiao X, Zhao W, Tian F, Zhou X, Zhang J, Huang T, Hou B, Du C, Wang S, Mo Y, Yu N, Zhou S, You J, Zhang Z, Huang G, Zeng X (2014) Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma. Tumour Biol 35:3755–3763. doi:10.1007/s13277-013-1497-1